Avidity Biosciences (RNA) News Today $28.92 +0.63 (+2.23%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside PotentialJanuary 17 at 11:37 AM | insidermonkey.comBank of America Securities Remains a Buy on Avidity Biosciences (RNA)January 16 at 3:03 AM | markets.businessinsider.comAvidity Biosciences: Strategic Advancements in Key Programs Drive Buy RatingJanuary 15 at 10:28 AM | markets.businessinsider.comBarclays Keeps Their Buy Rating on Avidity Biosciences (RNA)January 13, 2025 | markets.businessinsider.comAvidity Biosciences' (RNA) "Buy" Rating Reiterated at HC WainwrightJanuary 13, 2025 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Sees Large Volume Increase - Here's WhyAvidity Biosciences (NASDAQ:RNA) Sees Strong Trading Volume - What's Next?January 10, 2025 | marketbeat.comAvidity Biosciences' (RNA) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $72.00 price target on shares of Avidity Biosciences in a report on Friday.January 10, 2025 | marketbeat.comAvidity Biosciences plans BLA submission for delpacibart zotadirsenJanuary 9, 2025 | markets.businessinsider.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2025 | prnewswire.comAvidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025January 8, 2025 | prnewswire.comAvidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Buy" by AnalystsShares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have been given a consensus rating of "Buy" by the eleven analysts that are covering the stock, MarketBeat Ratings reports. Eleven analysts have rated the stock with a buy rating. The average 1-year price objective among brokers thJanuary 2, 2025 | marketbeat.comWhy Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?January 1, 2025 | msn.comAvidity Biosciences (NASDAQ:RNA) Trading Down 5.4% - Here's WhyAvidity Biosciences (NASDAQ:RNA) Trading Down 5.4% - Should You Sell?December 30, 2024 | marketbeat.comAvidity Biosciences Inc Ordinary SharesDecember 28, 2024 | morningstar.comFranklin Resources Inc. Buys 50,908 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Franklin Resources Inc. increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 229.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 73,047 shares of the biotechnology company's stock after buyingDecember 25, 2024 | marketbeat.comWhat is Chardan Capital's Estimate for RNA FY2024 Earnings?Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) - Equities researchers at Chardan Capital reduced their FY2024 earnings per share estimates for shares of Avidity Biosciences in a note issued to investors on Wednesday, December 18th. Chardan Capital analyst K. Nakae now anticipates that the bDecember 23, 2024 | marketbeat.comPromising Advancements and Strategic Growth: A Buy Rating for Avidity BiosciencesDecember 22, 2024 | markets.businessinsider.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 20, 2024 | prnewswire.comHC Wainwright & Co. Initiates Coverage of Avidity Biosciences (RNA) with Buy RecommendationDecember 20, 2024 | msn.comAvidity Biosciences (NASDAQ:RNA) Shares Up 3.2% - Time to Buy?Avidity Biosciences (NASDAQ:RNA) Stock Price Up 3.2% - Time to Buy?December 20, 2024 | marketbeat.comAvidity Biosciences initiated with a Buy at H.C. WainwrightDecember 20, 2024 | markets.businessinsider.comWhat 8 Analyst Ratings Have To Say About Avidity BiosciencesDecember 20, 2024 | benzinga.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells 11,151 Shares of StockDecember 20, 2024 | insidertrades.comAvidity Biosciences (NASDAQ:RNA) Coverage Initiated at HC WainwrightHC Wainwright assumed coverage on shares of Avidity Biosciences in a research note on Friday. They set a "buy" rating and a $72.00 target price on the stock.December 20, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 11,151 SharesAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CFO Michael F. Maclean sold 11,151 shares of the firm's stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $32.66, for a total transaction of $364,191.66. Following the sale, the chief financial officer now owns 82,942 shares of the company's stock, valued at $2,708,885.72. This trade represents a 11.85 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.December 19, 2024 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 12,742 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider W. Michael Flanagan sold 12,742 shares of the business's stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $32.66, for a total transaction of $416,153.72. Following the completion of the transaction, the insider now directly owns 72,647 shares of the company's stock, valued at approximately $2,372,651.02. This represents a 14.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.December 19, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells $1,040,384.30 in StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CEO Sarah Boyce sold 31,855 shares of the stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $32.66, for a total transaction of $1,040,384.30. Following the completion of the sale, the chief executive officer now owns 265,308 shares of the company's stock, valued at approximately $8,664,959.28. The trade was a 10.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.December 19, 2024 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 25,000 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider Teresa Mccarthy sold 25,000 shares of the company's stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $33.26, for a total transaction of $831,500.00. Following the completion of the sale, the insider now directly owns 94,018 shares of the company's stock, valued at $3,127,038.68. The trade was a 21.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.December 18, 2024 | marketbeat.comGeode Capital Management LLC Has $118.77 Million Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Geode Capital Management LLC raised its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 14.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,585,303 shares of the biotechnology company's stock afteDecember 18, 2024 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Down - Here's What HappenedAvidity Biosciences (NASDAQ:RNA) Shares Gap Down - Should You Sell?December 17, 2024 | marketbeat.comBarclays PLC Has $11.74 Million Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Barclays PLC boosted its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 68.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 255,699 shares of the biotechnology company's stock after purchasing an additionaDecember 17, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Lord Abbett & CO. LLCLord Abbett & CO. LLC increased its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 30.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 539,207 shares of the biotechnology company's stoDecember 16, 2024 | marketbeat.comW. Michael Flanagan Sells 24,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockDecember 14, 2024 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $858,480.00 in StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider W. Michael Flanagan sold 24,000 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $35.77, for a total transaction of $858,480.00. Following the sale, the insider now owns 85,389 shares of the company's stock, valued at approximately $3,054,364.53. This represents a 21.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.December 13, 2024 | marketbeat.comAvidity Biosciences (RNA) Receives a Buy from TD CowenDecember 13, 2024 | markets.businessinsider.comNeo Ivy Capital Management Invests $762,000 in Avidity Biosciences, Inc. (NASDAQ:RNA)Neo Ivy Capital Management bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 16,596 shares of the biotechnology company's stock, valued at apDecember 12, 2024 | marketbeat.comState Street Corp Purchases 1,386,087 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)State Street Corp increased its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 41.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,706,106 shares of the biotechDecember 12, 2024 | marketbeat.comAvidity Biosciences Advances With FDA Clearance And Promising Data For Rare DiseasesDecember 11, 2024 | seekingalpha.comAvidity Biosciences (NASDAQ:RNA) Stock Quotes, Forecast and News SummaryDecember 11, 2024 | benzinga.comCastleark Management LLC Acquires New Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Castleark Management LLC bought a new position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 57,110 shares of the biotechnology company's stock, valued at approximaDecember 8, 2024 | marketbeat.comWellington Management Group LLP Acquires 3,228,923 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Wellington Management Group LLP lifted its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 84.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,030,949 shares of the biotechnology company's stock aDecember 8, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Recommendation of "Buy" from AnalystsShares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have earned an average recommendation of "Buy" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1-year price objeDecember 8, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Acquired by RA Capital Management L.P.RA Capital Management L.P. grew its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 16.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,300,408 shares of the biotDecember 5, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) is RTW Investments LP's 3rd Largest PositionRTW Investments LP lowered its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 7.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,132,870 shares of the biotechnology company's stock after selling 673,968 shaDecember 5, 2024 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Bought by Janus Henderson Group PLCJanus Henderson Group PLC grew its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 33.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,896,166 shares of the biotechnology company's stock afteDecember 4, 2024 | marketbeat.comCinctive Capital Management LP Trims Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Cinctive Capital Management LP reduced its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 43.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,554 shares of the biotechnology coDecember 3, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Lowers Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)The Manufacturers Life Insurance Company lessened its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 5.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 257,456 shares of the biotechnology company's stock after sellDecember 3, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 197,065 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Charles Schwab Investment Management Inc. raised its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 24.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 990,182 shares of the biotechnology company'sDecember 2, 2024 | marketbeat.comAlethea Capital Management LLC Reduces Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Alethea Capital Management LLC cut its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 15.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 427,454 shares of the biotechnologyDecember 1, 2024 | marketbeat.comFmr LLC Acquires 689,729 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Fmr LLC boosted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,848,776 shares of the biotechnology company's stock afteNovember 28, 2024 | marketbeat.com Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Media Mentions By Week RNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼0.200.53▲Average Medical News Sentiment RNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼56▲RNA Articles Average Week Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Today Summit Therapeutics News Today Moderna News Today Dr. Reddy's Laboratories News Today Catalent News Today Sarepta Therapeutics News Today Qiagen News Today Vaxcyte News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNA Stock Alerts